AI assistant
CorMedix Inc. — Director's Dealing 2014
Jul 2, 2014
32333_dirs_2014-07-02_6a610e35-03d0-4c38-9a33-e3e2d847a1d2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2014-06-30
Reporting Person: MILBY RANDY (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-06-30 | Common Stock, $0.001 par value per share | P | 2732 | $1.83 | Acquired | 2732 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.001 par value per share | 196243 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.02 | 2024-01-09 | Common Stock, $0.001 par value per share (100000) | 100000 | Direct |
| Series C-3 Non-Voting Convertible Preferred Stock | $1 | Common Stock, $0.001 par value per share (237000) | 23700 | Direct | |
| Warrant (right to purchase Common Stock) | $1.25 | 2020-01-08 | Common Stock, $0.001 par value per share (118500) | 118500 | Direct |
| Series C-3 Non-Voting Convertible Preferred Stock | $1 | Common Stock, $0.001 par value per share (13000) | 1300 | Indirect | |
| Warrant (right to purchase Common Stock) | $1.25 | 2020-01-08 | Common Stock, $0.001 par value per share (6500) | 6500 | Indirect |
| Stock Option (right to buy) | $0.9 | 2023-03-20 | Common Stock, $0.001 par value per share (500000) | 500000 | Direct |
| Stock Option (right to buy) | $0.68 | 2022-12-05 | Common Stock, $0.001 par value per share (100000) | 100000 | Direct |
| Stock Option (right to buy) | $0.29 | 2022-05-14 | Common Stock, $0.001 par value per share (50000) | 50000 | Indirect |
Footnotes
F1: This purchase of newly issued shares was pursuant to an automatic payroll deduction stock purchase plan.
F2: The reporting person beneficially owns these securities through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control).
F3: The option vested 100% on January 10, 2014.
F4: On January 8, 2014, the reporting person acquired in a private placement (i) 23,700 shares of the Company's Series C-3 Non-Voting Convertible Prefered Stock, each share is convertible into 10 shares of the Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
F5: On January 8, 2014, the reporting person, through his ownership in MW Bridges LLC (an entity through which he has voting and investment control), acquired in a private placement (i) 1,300 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of the Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
F6: These options vest based on performance milestones running through December 31, 2014.
F7: These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
F8: These options vested 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate on July 5, 2013.